Spots Global Cancer Trial Database for Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases

Official Title: Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases

Study ID: NCT01970644

Conditions

Neoplasm Metastases

Interventions

Gamma knife radiosurgery

Study Description

Brief Summary: Cancer which spreads to the brain (brain metastases) is a common and significant problem. Historically, whole-brain radiotherapy has been used to treat these patients but has a negative effect on cognition. Radiosurgery is an alternative treatment with potential for fewer cognitive side effects. The impact of radiosurgery alone on the cognitive function of patients with multiple brain metastases is not well studied. We propose a pilot study at the Winnipeg Centre for Gamma Knife Surgery to examine this issue.

Detailed Description: Patients with \>=4 brain metastases will undergo Gamma Knife radiosurgery to a dose of 15-20 Gy, depending on the maximum tumour diameter and number of metastases. A number of neurocognitive, quality of life, and toxicity assessments will be performed at baseline and at 6 weeks post-radiosurgery, then at months 4, 6, 12, 18, and every 6 months thereafter.